hyaluronidase

Disclaimer to the Online Edition

This Manual has been designed for use in the NICU at London Health Sciences Centre (LHSC), London, Ontario, Canada, and represents clinical practice at this institution. The information contained within the Manual may not be applicable to other centres. If users of this Manual are not familiar with a drug, it is recommended that the official monograph be consulted before it is prescribed and administered. Any user of this information is advised that the contributors, Editor and LHSC are not responsible for any errors or omissions, and / or any consequences arising from the use of the information in this Manual.

hyaluronidase

Indication

  • Management of IV extravasations (leakage of an IV fluid out of a vein and into surrounding tissue)
  • Not for the management of extravasation due to vasoactive medications (E.G. DOBUTamine, DOPamine, EPINEPHrine, norepinephrine, phenylephrine or vasopressin).

Dosage Guidelines

  • Use 2 separate 0.2 mL injections of a 150 units/mL solution into the extravasation site at the leading edge

Administration

  • SUBCUTANEOUSLY by MD/NP only
  • Use a 25 gauge or smaller needle and change needle after each injection

Adverse Effects

  • Injection site reaction

Comments

  • NOT the agent of choice for management of extravasation of vasoactive medications
  • Do NOT inject around infected or inflamed areas
  • Most effective if administered within 1 hour of extravasation but still effective up to 12 hours after

Supplied As

  • 150 units ampoule (refrigerated)

References

LexiComp Sick Kids, LexiComp Pediatric and Neonatal and Neofax